Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.19
Views: 267

Dr Edward B. Garon - UCLA, Los Angeles, USA

Dr Edward B. Garon presents results at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from the KEYNOTE-001 clinical trial.

Following treatment with the immunotherapy drug pembrolizumab, 23.2% of people who had not previously been treated with chemotherapy and 15.5% of previously-treated patients were alive after five years.

​Watch the interview here.

Watch a comment from Dr David Graham here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation